CYP26A1 and colorectal carcinoma: 4.4. Clinical Significance of Our Results That Show CYP26A1 Inhibitors, Which Block RA Metabolism, Sensitize CRC Cells to the Anti-Proliferative Effect of Drugs That Downregulate WNT Signaling